Capivasertib and Ipatasertib act as AKT inhibitors to block the activation of AKT (protein kinase B), thereby preventing the phosphorylation and inactivation of pro-apoptotic proteins and promoting cell cycle arrest and apoptosis in cancer cells. Here, AKT1 is linked to cancer.